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Summary paragraph  
Most psychiatric disorders are moderately to highly heritable. The degree to which genetic 
variation is unique to individual disorders versus shared across disorders is unclear. We 
use genome-wide genotype data from the Psychiatric Genomics Consortium (PGC) of cases 
and controls for schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder 
(MDD), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder 
(ADHD). We apply univariate and bivariate methods for estimation of genetic variation 
within and covariation between disorders. SNPs explained 17-29% of the variance in 
liability. The genetic correlation calculated from common SNPs is high for SCZ/BPD 
(0.68±SE 0.04), moderate for SCZ/MDD (0.43±0.06), BPD/MDD (0.47±0.06), ADHD/MDD 
(0.32±0.07), low between SCZ/ASD (0.16±0.06), and non-significant for other pairs of 
disorders as well as with the negative control of Crohn’s Disease. This empirical evidence 
for a shared genetic etiology between psychiatric disorders can inform nosology and 
encourages investigation of common pathophysiologies for the related disorders. 
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Text  
 
Current classification of psychiatric disorders reflects clinical syndromes with largely 
unknown etiology and is based on historical descriptions provided by prominent clinicians 
over the last 125 years. Family (including twin and adoption) studies provide consistent 
evidence that genetic factors are involved in these syndromes1. In principle, family studies 
allow quantification of shared genetic etiology, through estimation of heritability (the 
proportion of variance in liability attributable to additive genetic factors) of disorders and 
the genetic correlation between them.  However, difficulties in ascertaining samples of 
sufficient size mean that estimates of genetic correlations are few. Nonetheless, family 
studies suggest correlated familial-genetic liabilities to BPD and SCZ2,3,  BPD and MDD2,3 and 
ASD and ADHD4-6 (Supplementary Table 1). Phenotypic and genetic overlap has also been 
suggested for ASD and SCZ7-11, ASD and BPD9, BPD and ADHD12 and MDD and ADHD13. Some 
of these relationships have been supported by recent evidence of shared molecular risk 
factors14-16, but the extent of these relationships remains unclear given the small proportion 
of risk associated with these individually identified variants.  
 
The genomics era provides new opportunities to explore the shared genetic etiology of 
disorders. Genome-wide association studies (GWAS) assess common genetic polymorphisms 
(e.g., SNPs) at several hundred thousand positions in the genome. The experimental 
paradigm of GWAS is identification of individual variants associated with case-control 
status17. However, these data can be used to estimate the total variance in liability explained 
by SNPs (“SNP-heritability”, SNP-h2) through estimation of genetic similarities (relationships) 
between cases and controls using SNP genotypes18,19. The pair-wise genetic relationships 
that contribute to the estimate are very small, but the large number of pairwise 
relationships in a case-control sample generates estimates with reasonable precision. The 
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SNP-h2 is an estimate of the total variance in liability to disease explained by the SNPs 
together. Genetic variation is estimated when case-case pairs and control-control pairs are, 
on average, more similar genome-wide than case-control pairs. The SNP-h2 is a lower bound 
for the total narrow sense heritability, as the former cannot include contributions from 
causal variants not tagged by the measured SNPs, mostly less common and rare causal 
variants.  A bivariate extension20 of these genome-wide methods estimates the genetic 
correlation (SNP-rg) explained by SNPs between case-control samples collected 
independently for two disorders (see online Methods). The correlation is positive when the 
cases of one disorder show higher genetic similarity to the cases of the other disorder than 
to their controls. A negative correlation is possible if the cases of one disorder are less 
similar genome-wide to the cases of the other disorder than they are to controls. A genetic 
correlation of zero is estimated if the genome-wide relationship between cases of one 
disorder is the same with cases as with controls of the other disorder. As a correlation, a 
high SNP-rg is achieved when the covariance term between the traits is similar in magnitude 
to the variance terms.  Therefore, we also report the SNP-coheritability between pairs of 
disorders, which is the covariance between disorders on the liability scale and allows 
comparison of the shared liability attributable to SNPs on the same scale as the SNP-h2. 
Here, we apply the univariate and bivariate methods to the five disorders of the PGC:  SCZ21, 
BPD22, MDD23, ASD24,25 and ADHD26 analysed in the PGC cross-disorder group association 
study25, together with additional ADHD data sets27-30 (Table 1).  
 
RESULTS 
SNP-heritabilities for the five disorders  
In our linear mixed model we estimate the variance in case-control status explained by 
SNPs18 (heritability on the observed scale, CC in Table 1). Cases in case-control samples are 
highly ascertained compared to in the population, and since the different disorder cohorts 
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have different proportions of cases, the CC estimates are difficult to interpret and compare. 
For this reason, we report SNP-h2 on the liability scale, in which a linear transformation18 is 
applied based on a user-specified estimate of the disorder risk of the study-base population 
(disorder risk, K). For each disorder we consider three values of K (Table 1) and we convert 
the SNP-h2 to a predicted risk to 1st-degree relatives (SNP-1st) given K. We benchmark the 
SNP-1st risk to risk to 1
st-degree relatives (1st) consistent with estimates of heritabilities 
reported from family studies given K. Our estimates of SNP-1st are robust, and of SNP-h
2 are 
reasonably robust, to the likely range of K and show that an important part of the 
heritabilities or familial risk estimated from family studies are associated with common 
SNPs. Twice the standard error of estimates approximates the magnitude of parameter that 
is possible to detect as significantly different from zero given the available sample sizes31. 
 
SNP-coheritabilities and SNP-correlations (SNP-rg) between all pairwise combinations of 
disorders 
The relationships between disorders are expressed as SNP-coheritabilities (Fig. 1). The SNP-
rg is high for SCZ/BPD 0.68 (s.e. 0.04), moderate for SCZ/MDD 0.43 (0.06), BPD/MDD 0.47 
(0.06), ADHD/MDD 0.32 (0.07), low between SCZ/ASD 0.16 (0.06), and non-significant for 
other pairs of disorders (Supplementary Table 1). The SNP-rg correlation is expected to be 
equal to the rg from family studies only if the genetic correlation is the same across the 
allelic frequency spectrum and if the linkage disequilibrium between genotyped and causal 
variants is similar for both disorders. The sample size for ASD is the smallest but still can 
detect correlations of > |0.18| to be different from zero in bivariate analyses with all other 
disorders.  
 
Our results provide empirical evidence that SCZ, BPD and MDD have a shared genetic 
etiology. Since some SCZ and BPD cohorts were collected in the same clinical environments, 
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we investigated possible impact of non-independent collection of SCZ/BPD samples sets but 
found no significant change in the estimates (Supplementary Table 2). The correlation 
between SCZ and ASD is significant but small (0.16 s.e. 0.06, p = 0.0071). In general, our 
analyses suggest that while common genetic variants contribute to both childhood-onset 
disorders (ASD, ADHD) and disorders usually diagnosed after childhood (SCZ, BPD, MDD), the 
sharing of common variants between them is modest.  
The pattern of our results (i.e., which pairs of disorders demonstrate genetic overlap) is 
consistent with the polygenic profile score32 results from the PGC cross-disorder analyses25. 
The profile score method uses SNP associations from one disorder to construct a linear 
predictor in another disorder. The profile scores explained small but significant proportions 
of the variance25, expressed as Nagelkerke’s R2 (maximum of 2.5% between SCZ and BPD). 
To achieve a high R2 requires accurate estimation of effect sizes of individual SNPs and 
depends on the size of the discovery sample. In contrast, our approach uses SNPs to 
estimate genome-wide similarities between pairs of individuals, resulting in unbiased 
estimates of the relationships between disorders, with larger sample sizes generating 
smaller standard errors of the estimates. Our estimates are on the liability scale, allowing 
direct comparison to genetic parameters estimated in family studies, whereas a genetic 
interpretation of Nagelkerke’s R2 is less straightforward33. 
 
Genomic partitioning of SNP-heritabilities and SNP-coheritabilities 
The heritabilities explained by SNPs can be partitioned according to SNP annotation by 
estimation of genetic similarity matrices from multiple, non-overlapping SNP sets. For the 
five disorders, and the five disorder pairs showing a significant SNP correlation, we 
partitioned the SNP-h2 and SNP-coheritabilities explained by functional annotation, 
allocating SNPs to one of three sets: i) in genes preferentially expressed in the central 
nervous system (CNS+)34,35, ii) in other genes and iii) not in genes, with genes defined with 
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50kb boundaries from their start/stop positions. The SNPs in the CNS+ gene set represented 
0.20 of the total set, both in number and megabases. However, the proportion of the 
variance explained by SNPs attributable to this SNP set is significantly greater than 0.20 for 
SCZ (0.30, p = 7.6 e-08) and BPD (0.32,p = 5.4e-06) and for the SCZ/BPD coheritability (0.37, 
p = 8.5e-08, Fig. 2, Supplementary Table 3). For other disorders or pairs of disorders, the 
estimates explained by CNS+ SNPs do not differ from chance expectation (Supplementary 
Table 3), although their large standard errors suggest we cannot address this question with 
precision. For the SCZ/BPD data we also partitioned the heritabilities explained by SNPs by 
minor allele frequency (MAF) (Supplementary Table 4) and by chromosome (Supplementary 
Figure 1). The high standard errors on estimates limits interpretation; but the results are 
consistent with a polygenic architecture of many common variants of small effect dispersed 
throughout the genome. The MAF partitioning suggests that an important part of the 
variance explained by SNPs is attributable to common causal variants (this was investigated 
in detail for SCZ35), but the low contribution to the total variance explained from SNPs with 
MAF < 0.1 reflects, at least in part, under-representation of SNPs with low MAF in the 
analysis (minimum MAF = 0.01) relative to those present in the genome. 
 
Within disorder heterogeneity 
In order to benchmark the estimates of genetic sharing across disorders, we estimated 
sharing between data sub-sets of the same disorder. We split the data for each disorder into 
2 or 3 independent sets and estimated the SNP-h2 from each subset, and the SNP-
coheritability between each pair of subsets within a disorder (Fig. 3a, Supplementary Table 
5 and 6).  The estimates of SNP-h2 from the data sub-sets are typically higher than the SNP- 
h2 from the combined sample; we note that published estimates from individual cohorts of 
BPD18, MDD36 and ASD37 were also higher.   Since both traits in these data sub-set bivariate 
analyses are from the same disorder, the SNP-coheritability is also an estimate of the SNP- 
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h2 for the disorder, but these are generally lower than the estimates of SNP-heritability from 
individual data sub-sets. These results generate SNP-correlations that are less than one, and 
sometimes significantly so (Supplementary Table 6).  The SCZ/BPD SNP correlation (0.68 s.e. 
0.04) is of comparable magnitude as the SNP-correlations between BPD data sets (0.63 s.e. 
0.11, 0.88 s.e. 0.09 and 0.55 s.e. 0.10 ;  Fig 3a,b for SNP coheritabilities), adding further 
weight to the conclusion that SCZ and BPD may be part of the same etiological spectrum.  
 
The estimates of heritability from both univariate (Fig. 3a red/pink bars) and bivariate 
analyses (Fig. 3a blue bars) are more heterogeneous for BPD, MDD and ADHD than for SCZ 
and ASD. Several reasons could explain why SNP-heritabilities from univariate analyses of a 
single data set could generate higher estimates than from bivariate analyses of independent 
data sets35, including loss of real signal or dilution of artefacts. Loss of real signal may occur 
because individual cohorts are more homogeneous, both phenotypically (e.g., use of the 
same assessment protocols), and genetically (e.g. because linkage disequilibrium (LD) 
between causal variants and analyzed SNPs might be higher within than between cohorts). 
On the other hand, artefacts could generate consistent differences in case vs control 
genotypes within case-control data sets. In the derivation of our methodology18, we 
emphasised that any factors making SNP genotypes of cases more similar to other cases, and 
controls more similar to controls, will produce SNP-heritability. The fitting as covariates of 
principal components derived from the SNP data corrects both for population stratification 
and for genotyping artefacts, but residual population stratification38 could remain, although 
this bias should be small38,39. Partitioning SNP-heritability by chromosome in analyses where 
each chromosome is fitted individually compared to analyses where all chromosomes are 
fitted jointly is an empirical strategy to assess residual stratification35,40 and we find no such 
evidence here (Supplementary Figure 1). Stringent QC helps (as applied here) to remove 
artefacts, but artefactual differences between cases and controls may remain, particularly 
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for data sets in which cases and controls have been genotyped independently41. As more 
data sets accumulate, the contributions from artefacts are diluted since the random 
directional effects of artefacts (including population stratification) are not consistent across 
data sets. For this reason, significant SNP-coheritabilities are unlikely to reflect artefacts and 
provide a lower bound on SNP-heritability.  
 
Pseudo-controls 
One strategy adopted in GWAS to guard against artefacts of population stratification is to 
genotype trio samples (cases and their parents) and then analyse the data as a case-control 
sample with controls generated as genomic complements of the cases (i.e. “pseudo-
controls”).  The ADHD subset 1 and most of the ASD sample are comprised of case-pseudo 
control samples and, consistent with limiting the impact of artefacts from population 
stratification or genotyping, it is noted that the lowest SNP-heritability of the 5 psychiatric 
disorders is for ASD and that the estimate of SNP-heritability is lower for ADHD subset 1 
than for ADHD subset 2. However, under a polygenic model, assortative mating42 or 
preferential ascertainment of multiplex families could diminish the expected mean 
difference in liability between pseudo-controls and cases37, which would result in an 
underestimation of SNP-heritability from case/pseudo-control compared to case/control 
analyses and also non-zero estimates of SNP-heritability from pseudo-control/control 
analyses as shown in analysis of ASD data37.  
 
Negative control – SNP-coheritabilities with Crohn’s Disease 
As a negative control analysis, we conducted bivariate analyses between each of the PGC 
data sets with Crohn’s Disease (CD) from the International IBD Genetics Consortium 
(IIBDGC)43. While onset of MDD is not uncommon after diagnosis with CD44, and while 
gastrointestinal pathology is commonly comorbid with ASD45, there is no strong evidence of 
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a familial relationship between psychiatric disorders and CD. Despite a substantial SNP-h2 for 
CD (0.19 s.e. 0.01), none of the SNP-coheritabilities with the psychiatric disorders differed 
significantly from zero (Fig. 3c, Supplementary Table 7, Supplementary Note). Lastly, the 
genomic partitioning by annotation of variance in CD explained by SNPs showed, as 
expected, no excess of variance attributable to SNPs in the CNS+ gene set (Fig. 2). Our 
results provide no evidence for common genetic pleiotropy between CD and ASD consistent 
with a non-genetic e.g. microbial47 explanation for the comorbid gastrointestinal symptoms 
in ASD. 
 
Potential impact of misclassification of disorders 
Misclassification between disorders could inflate estimates of genetic correlation/ 
coheritability48. Indeed, some level of misclassification between psychiatric disorders is 
expected.   For example, longitudinal studies4950. of first admissions with psychosis based on 
research interviews showed that with long term follow-up. ~15% of subjects initially 
diagnosed with bipolar disorder were re-diagnosed with schizophrenia while ~4% of 
schizophrenia diagnoses were re-classified as bipolar disorder. Cases selected for GWAS 
contributing to PGC to date are more likely to have achieved a stable diagnosis compared to 
first admission cases. However, assuming these levels of misclassification, the genetic 
correlation between BPD and SCZ of “true” diagnoses is still high, estimated48 to be 0.55. 
Likewise, since a modest proportion of cases diagnosed with MDD followed over time 
ultimately meet criteria for BPD51 our estimated genetic correlation between these two 
disorders may be modestly inflated by misclassification. On the other hand, if moderate to 
high genetic correlations between the major adult disorders are true, then overlapping 
symptoms and misdiagnosis between disorders might be expected. The SNP-rg between SCZ 
and MDD also is unlikely to reflect misdiagnosis since misclassification between these 
disorders is rare51. Excluding the five of the 18 PGC-SCZ cohorts containing schizoaffective 
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disorder cases21 (Supplementary Table 8) or MDD cohorts ascertained from community 
rather than clinical settings (Supplementary Table 9) had little impact on the SNP-rg 
estimates .  
 
DISCUSSION 
Our results show direct, empirical, quantified, molecular evidence for an important genetic 
contribution to the five major psychiatric disorders. The SNP-h2 estimates for each disorder: 
SCZ 0.21 (s.e. 0.02), BPD 0.25 (s.e. 0.01), MDD 0.21 (s.e. 0.01), ASD 0.14 (s.e. 0.02), ADHD 
0.32 (s.e. 0.02) are considerably less than the heritabilities estimated from family studies 
(see Table 1). Yet they show that common SNPs make an important contribution to the 
overall variance, implying that additional individual common SNP associations can be 
discovered as sample size increases52. SNP- h2 are a lower bound of narrow sense heritability 
because they exclude contributions from some causal variants (mostly rare variants) not 
associated with common SNPs. Although the SNP-heritability estimate is similar for MDD as 
for other disorders, much larger sample sizes will be needed because the high disorder risk 
implies lower power for the same sample size53. The SNP- h2 are all lower than those 
reported for height (0.45 s.e. 0.03)40 but the estimates are in the same ball-park to those 
reported for other complex traits and diseases using the same QC pipeline, such as BMI 
(0.17 s.e. 0.03)40, Alzheimer’s Disease (0.24 s.e.0.03), multiple sclerosis (0.30 s.e.0.03) and 
endometriosis (0.26 s.e.0.04)41. 
Our results show molecular evidence for the sharing of genetic risk factors across 
key psychiatric disorders.  Traditionally, quantification of the genetic relationship between 
disorders has been thwarted by the need for cohorts of families or twins assessed for 
multiple disorders.  Problems of achieving genetically informative samples of sufficient size 
and without associated ascertainment biases for the rarer psychiatric disorders have meant 
that few studies have produced meaningful estimates of genetic correlations.  Importantly, 
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our estimates of heritability and genetic correlation are made using very distant genetic 
relationships between individuals, both within and between disorders, so that shared 
environmental factors are unlikely to contaminate our estimates. Likewise, our estimates are 
unlikely to be confounded by non-additive genetic effects, since the coefficients of non-
additive genetic variance between very distant relatives are negligible54.  
The estimates of SNP-genetic correlation (SNP-rg) between disorders reflect 
genome-wide pleiotropy of variants tagged by common SNPs and whether these are the 
same as correlations across the allelic frequency spectrum may differ between disorder 
pairs. For example, a high SNP-rg but a low genetic correlation estimated from family studies 
(rg) could reflect that the same common variants contribute to the genetic susceptibility of 
both disorders, while the diagnostic-specific variants are less common variants. For this 
reason, the comparison of SNP-rg with rg estimated from family studies is not 
straightforward. Nonetheless we benchmark our estimates in this way, calculating the 
increased risk of disorder B in first-degree relatives of probands with disorder A (A,B
the SNP-rg to allow comparison with literature values (Supplementary Table 1).   A meta-
analysis55 reported the increased risk of BPD in first-degree relatives of SCZ probands 
compared to first-degree relatives of control probands  (
maximum genetic correlation between them of 0.3 (assuming that the disorder risks for SCZ 
and BPD are both 1%, and their heritabilities are 81% and 75%, Table 1). However, a large-
scale Swedish family and adoption study56 estimated the genetic correlation between SCZ 
and BPD to be +0.60, similar to that found here.  Profiling scoring analyses using genome-
wide SNPs32 was the first to demonstrate clearly a genetic relationship based on molecular 
data, but quantification as a genetic correlation was not reported. The evidence of shared 
genetic risk factors for SCZ and BPD was strengthened by our analyses of the CNS+ gene set 
where we saw a clear enrichment in variants shared by these two disorders.  
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Our finding of a substantial SNP-rg of +0.43 between SCZ and MDD is intriguing and 
contrary to conventional wisdom about the independence of familial risk for these disorders. 
However, since MDD is common, even a high genetic correlation implies only modest 
incremental risk.  Assuming that the disorder risks  and heritabilities for SCZ and MDD in 
Table 1, then a the genetic correlation between them of 0.43 predicts an increased risk of 
MDD in first-degree relatives of SCZ probands compared to first-degree relatives of control 
probands  ( -analysis of five studies interview-based research 
studies of families are broadly consistent with our results (  = 1.5, 95% CI 1.2-1.8, 
Supplementary Table 10), suggesting that familial coaggregation of MDD and SCZ reflects 
genetic effects rather than a consequence of living in a family environment that includes a 
severely ill family member. If replicated by future work, our empirical molecular genetic 
evidence of a partly shared genetic etiology for SCZ and MDD has important nosological and 
research implications, placing MDD as part of a broad psychiatric genetic spectrum. A shared 
genetic etiology between BPD and MDD has been shown in family studies2,3  but the SNP-rg 
of 0.47 is lower than the estimate of 0.65 from a twin study57.  
Our results show a small but significant SNP-rg between SCZ and ASD.  A lower 
genetic correlation between SCZ and ASD than between SCZ and BPD is consistent with the 
Swedish national epidemiological studies which reported higher odds ratios in siblings 
between SCZ and BPD56 than between SCZ and ASD9.  These results imply a modest overlap 
of common genetic etiologic processes in these two disorders consistent with emerging 
evidence from discovery of copy number variants where both shared variants (e.g  15q13.3, 
1q2.1 and 17q12 deletions58,59) and same gene but different variants (deletions associated 
with schizophrenia and duplications associated with autism, and vice versa10) have been 
reported. The small ASD sample size thwarted attempts of further explorative partitioning of 
the SNP coheritability between SCZ and ASD.  
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The lack of overlap between ADHD and ASD is surprising and not consistent with 
family and data linkage studies, which indicate that the two disorders share genetic risk 
factors5,6,60,61. Some rare copy number variants are seen in both disorders16.  As noted above, 
the use of pseudo-controls for many of the ASD and ADHD cohorts may impact on all results 
for these disorders. Ideally we would investigate the impact of pseudo-controls given the 
hierarchical diagnostic system (autism, but not autism spectrum is an exclusion criterion for 
most ADHD data sets) on estimates of the SNP-coheritability, but the small ASD sample size 
prohibits such analyses. We also found no overlap between ADHD and bipolar disorder 
despite meta-analytic support for an increased risk for ADHD in relatives of BPD I (a subtype 
of BPD with more extreme manic symptoms than the other major BPD subtype) patients and 
an increased risk for BPD I in relatives of ADHD patients 12. This could mean that the familial 
link between the two disorders is mediated by environmental risk factors or that the shared 
genetic factors are not part of the common allelic spectrum.   Alternatively, the etiologic link 
between ADHD and BPD might be limited to BPD I or early onset BPD12 which therefore is 
difficult for us to detect. Our finding of genetic overlap between ADHD and MDD is 
consistent with evidence from studies showing increased rates of ADHD in families of 
depressed probands and increased rates of depression in families of ADHD probands 12,13.  
Our results should be interpreted in the context of four potentially important 
methodological limitations.  First, any artefacts, that make SNP genotypes more similar 
between cases than between cases vs. controls could inflate estimates of SNP-heritability18, 
but to a much lesser extent SNP–coheritability. Second, the sample sizes varied considerably 
across the five disorders.  Although the SNP-h2 are expected to be unbiased, estimates from 
smaller samples are accompanied by larger standard errors, blurring their interpretation. 
Third, while applying similar diagnostic criteria, the clinical methods of ascertainment and 
the specific study protocols, including which specific interview instruments were employed, 
varied across sites. We cannot now determine the degree to which our results might have 
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been influenced by the between-site differences in the kinds of patients seen or in their 
assessments. Fourth, by combining samples from geographical regions, contributions from 
less common associated variants specific to populations are diluted compared to what could 
be achieved if the same sample size had been ascertained from a single homogeneous 
population.  
In summary, we report SNP-heritabilities that are significantly greater than zero for 
all five disorders studied. We have used the largest psychiatric GWAS data sets currently 
available and our results provide important pointers for future studies. Our results 
demonstrate that the dearth of significant associations from psychiatric GWAS to date, 
particularly for MDD, ASD and ADHD, reflects lack of power to detect common associated 
variants of small effect rather than absence of such variants. Hence as sample sizes increase 
the success afforded to other complex genetic diseases52 in progressing understanding of 
their etiology is achievable for psychiatric disorders, as already being shown for SCZ62. We 
also provide evidence for a substantial sharing of the genetic risk variants “tagged” by these 
SNPs for SCZ/BPD, BPD/MDD, SCZ/MDD, ADHD/MDD and, to a lesser extent, SCZ/ASD. Our 
results will likely contribute to efforts now underway to base psychiatric nosology on a 
firmer empirical footing. Furthermore, they will encourage investigations into shared 
pathophysiologies across disorders including potential clarification of common therapeutic 
mechanisms.  
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Table 1.  Univariate analyses: sample description, SNP-heritabilities and recurrence risk to 
first-degree relatives 
 
 SCZ BPD MDD ASD ADHD 
SNPs(imputed) 915354 995971 962093 982100 917066 
Cases 9087 6704 9041 3303 4163 
Controls 12171 9031 9381 3428a 12040a 
N cohorts 
 
17 11 9 8 8 
Primary Reference 21 22 23 24,25 26-30 
CCb (s.e.)  0.41 (0.015) 0.44 (0.021) 0.18 (0.017) 0.31 (0.046) 0.25 (0.020) 
Disorder risk for the study-base population (disorder risk, K) used in Figures and Supplementary Tables 
K 
 
0.01 0.01 0.15 0.01 0.05 
SNP-h2 (s.e.)  0.23 (0.008) 0.25 (0.012) 0.21 (0.021) 0.17 (0.023) 0.28 (0.023) 
1st-SNP (s.e)
 2.10 (0.05) 2.23 (0.08) 1.27 (0.03) 1.75 (0.14) 1.71 (0.07) 
1st 
 8.8 9.6 1.5 8.7 3.5 
Lower bound for disorder risk (K)  
K 
 
0.004 0.007 0.1 0.001 0.03 
SNP-h2 (s.e.)  0.19 (0.007) 0.23 (0.010) 0.19 (0.020) 0.11 (0.017) 0.24 (0.020) 
1st-SNP (s.e)
 2.14 (0.06) 2.25 (0.08) 1.31 (0.03) 1.79 (0.15) 1.77 (0.07) 
1st 
 14.4 11.7 1.7 29.4 4.5 
Upper bound for disorder risk (K)  
K 
 
0.012 0.015 0.2 0.015 0.08 
SNP-h2 (s.e.)  0.24 (0.009) 0.27 (0.013) 0.23 (0.023) 0.19 (0.028) 0.32 (0.026) 
1st-SNP (s.e)
 2.10 (0.05) 2.20 (0.07) 1.24 (0.02) 1.74 (0.13) 1.65 (0.06) 
1st  8.0 7.7 1.4 7.0 2.8 
Heritability estimated from twin/family studies63 
h2 0.81 0.75 0.37 0.80 0.75 
 
SCZ: schizophrenia, BPD: bipolar disorder, MDD: major depressive disorder, ASD: autism 
spectrum disorders, ADHD: attention deficit hyperactivity disorder. CC=SNP-heritability 
estimated on case-control scale. SNP-h2 SNP-heritability on liability scale given assumed K. 
All estimates of SNP- 2h  are highly significantly different from zero.1st-SNP recurrence risk to 
first degree relatives calculated from SNP-h2 liability and K.  1st recurrence risk to first 
degree relatives calculated from h2 from twin/family studies and K . a) some cohorts include 
cases and pseudo-controls where pseudo-controls are the genomic complements of the 
cases derived from genotyping of proband-parent trios.  
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Figure 1. Evidence for genome-wide pleiotropy between psychiatric disorders. a. 
Proportion of variance in liability (SNP-heritability), and proportion of covariance in liability 
between disorder (SNP-coheritability) for 5 major psychiatric disorders. 95% error bars are 
estimate ± 1.96 standard error.  
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Figure 2 Genomic partitioning of SNP-heritability/SNP-coheritability by annotation. 
Proportion of SNPs attributable to genes in CNS+ set (red bar), proportion of SNP-heritability 
explained by SNPs attributed to SNPs in CNS+ set (dark green bar), proportion of SNP-
coheritability attributed to SNPs in CNS+ set (light green bar), proportion of SNP-heritability 
for Crohn’s Disease attributed to SNPs in CNS+ set (orange bar). 95% error bars are estimate 
± 1.96 standard error. *** p< 10-5 from test that proportion of heritability explained by 
SNPs = proportion of SNPs.  
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Figure 3  SNP-heritabilities  and coheritabilities. a) For each disorder the SNP-heritabilities 
are estimated from univariate analyses of the full data set (dark green bars) or from subsets 
(red/pink bars). They are also estimated from bivariate analyses in which different subsets of 
the same disorder comprise the two traits (blue bars). Test of heterogeneity of estimates, p-
value for Cochrane’s Q, SCZ: 0.3, BPD: 1x10-6, MDD: 4 x10-3, ADHD: 9x10-6, ASD: 0.99 Higgins’ 
I2, SCZ: 21%, BPD: 86%, MDD: 71% ADHD: 91% ASD:0 b) For comparison the coheritabilities 
using the full data sets from Figure 1.  c) As a negative control, estimates of coheritabilities 
with Crohn’s Disease (CD), a disease not expected to be genetically related to psychiatric 
disorders, and between BPD. 95% error bars are estimate ± 1.96 standard error.  
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Methods  
Data & quality control (QC) 
A summary of the data available for analysis is listed in Table 1 and comprise data used in 
the PGC-Cross Disorder Group analysis25 together with newly available ADHD samples27-30. 
Data from all study cohorts were processed through the stringent PGC pipeline25. Imputation 
of autosomal SNPs used the CEU+TSI Hapmap Phase 3 data as the reference panel21. For 
each analysis (univariate or bivariate), we retained only SNPs that had minor allele 
frequency > 0.01 and imputation R2 > 0.6 in all contributing cohort sub-samples (imputation 
cohorts). Different QC strategies were investigated in detail for the raw and PGC imputed 
genotyped data of the International Schizophrenia Consortium, a subset of the PGC SCZ 
sample35. The CD samples from the International IBD Genetics Consortium (IIBDGC)43 were 
processed through the same QC and imputation pipeline as the PGC data, generating a data 
set of 5054 cases and 11496 controls from 6 imputation cohorts. 
 
In each analysis, individuals were excluded to ensure that all cases and controls were 
completely unrelated in the classical sense, so that no pairs of individuals had a genome-
wide similarity relationship greater than 0.05 (equivalent to about second-cousins). This 
procedure removed ancestry outliers (over and above those already removed in the PGC QC 
pipeline, Supplementary Figures 2-6) and ensured that overlapping control sets were 
allocated randomly between disorders in the bivariate analyses. Exact numbers of cases and 
controls used in each analysis are listed in Supplementary Tables 1-10.  
 
Linear mixed model for estimation of SNP-heritability and SNP-coheritability 
We use the methods presented in Lee et al.18,35 Briefly, we estimate the variance in case-
control status explained by all SNPs using a linear mixed model, 
 21 
y=Xb +g+e
           (1)
 
where y is a vector of case (=1) or control (=0) status (the “observed scale”), β is a vector for 
fixed effects of the overall mean (intercept), sex, sample cohort and 20 ancestry principal 
components, g is the vector of random additive genetic effects based on aggregate SNP 
information, and e is a vector of random error effects. X is an incidence matrix for the fixed 
effects relating these effects to individuals. The variance structure of phenotypic 
observations is V(y) = 22 eg  IAV  , where  is additive genetic variance tagged by the 
SNPs,  is error variance, A is the realized similarity relationship matrix estimated from SNP 
data19 and I is an identity matrix. All variances are estimated on the observed case-control 
scale and are transformed to the liability scale, which requires specification of the disorder 
risk, K, to estimate SNP-h2. Risk to first-degree relatives is calculated from K and SNP-h2 
based on the liability threshold model64. 
The bivariate analyses use a bivariate extension of equation (1)20. The two traits are 
measured on different individuals, but the equations are related through the genome-wide 
similarities estimated from SNPs. Genetic and residual variances for the traits are estimated 
as well as the genetic covariances g12 . The genetic correlation coefficient (rg) is 
s g12/( 21 gg  ) and is approximately the same on the observed case-control scale as on the 
liability scale20 so does not depend on specifications of K. The covariance, s g12, can be 
transformed to the liability scale accounting for assumed disorder risks and proportions of 
cases and controls in the samples of each disorder20 and it equals the coheritability54, rgh1h2. 
We used the approximated chi-square test statistic (estimate/s.e.)2 to test if estimates were 
significantly different from zero. We checked that this simple approximation agreed well 
with the more formal and computer-intensive likelihood ratio test for several examples. 
Heterogeneity of SNP-heritabilities was tested using Cochran’s65  Q  and Higgins’66 I2, 
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acknowledging potential non-independence of the 6 estimates (3 subsets plus 3 subset 
pairs). 
Disorder risk for the study-base population (disorder risk, K) 
The estimates of SNP-h2 and SNP-coheritability from the linear model are on the case-
control scale and so depend partly on the proportion of cases and controls in the sample. 
The transformation to the liability scale allows benchmarking of SNP-h2 to estimates of 
heritability from family studies, and the transformation accounts for the proportion of cases 
in the sample and depends on the assumed disorder risk (K). The appropriate choice of K 
depends on the definitions of both the phenotype (including ascertainment strategy) and 
the population, which may differ between cohorts. We consider lower and upper bounds for 
K in Table 1 to cover the range of possible values. SNP-rg estimates are independent of scale 
and hence are not dependent on the choice of K. 
Genome partitioning linear mixed model 
We partitioned the variance explained by the SNPs in several ways. For example, for the 
univariate linear model y=X b + gt
t=1
n
å +e   with V(y) = 
where  n is the number of subsets from any non-overlapping partitioning of SNPs; n = 22 for 
the joint analysis by chromosome, n = 5 for the analysis by MAF bin and n = 3 for the analysis 
of SNP by gene annotation in which SNPs were classed as “CNS+ genes” (2,725 genes 
representing 547 Mb), SNPs in “other genes” (14,804 genes representing 1,069 Mb) and the 
remaining SNPs “not in genes”.  Gene boundaries as ± 50kb from 3’ and 5’ UTRs of each gene 
and the CNS+ genes were the four sets identified by Raychaudhuri et al.34 (one set 
comprised genes expressed preferentially in the brain compared to other tissues and the 
other three sets comprised genes annotated to be involved in neuronal activity, learning and 
synapses). The CNS+ set was found to explain more of the SNP-heritability than expected by 
 
V = A
t
t=1
n
å s gtc
2 + Is
e
2
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chance for schizophrenia35. All methods have been implemented into the freely available 
GCTA software67. 
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